Johnson & Johnson and Procter & Gamble are highlighted as two safe S&P 500 dividend stocks ideal for retirees seeking reliable income. Johnson & Johnson has raised its dividend for 64 consecutive years, supported by strong free cash flow and diverse medical products. Procter & Gamble, with 70 years of dividend increases, benefits from essential household products and robust cash flow, despite facing cost inflation pressures. Both companies have strong balance sheets and long dividend growth records, making them attractive for income-focused investors looking to hold stocks for decades.
Johnson & Johnson trades at USD 264.07 on Pluang as of Oct 26, 2026, 20:01 WIB, with a slight 1-day gain of 0.10%. The stock shows a dividend yield of 2.03%, appealing to income-focused investors. Its market cap stands at $635.07 billion, reflecting its strong position in the health sector.
New Phase 3 PROTEUS substudy results show that adding apalutamide plus androgen deprivation therapy (ADT) before and after surgery reduces the risk of prostate cancer recurrence or death by 62% compared to surgery alone in high-risk localized or loca...
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
More than 200 companies are actively developing over 240 Alzheimer's disease therapies, with around 20 drugs in late-stage trials and many others in earlier phases. Key players include Eli Lilly, Biogen, Johnson & Johnson, and Eisai, focusing on inno...
